Elevation of pro-inflammatory cytokine levels following anti-resorptive drug treatment is required for osteonecrosis development in infectious osteomyelitis

Mayu Morita, Ryotaro Iwasaki, Yuiko Sato, Tami Kobayashi, Ryuichi Watanabe, Takatsugu Oike, Satoshi Nakamura, Yosuke Keneko, Kana Miyamoto, Kazuyuki Ishihara, Yoichiro Iwakura, Ken Ishii, Morio Matsumoto, Masaya Nakamura, Hiromasa Kawana, Taneaki Nakagawa, Takeshi Miyamoto

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Various conditions, including bacterial infection, can promote osteonecrosis. For example, following invasive dental therapy with anti-bone resorptive agents, some patients develop osteonecrosis in the jaw; however, pathological mechanisms underlying these outcomes remain unknown. Here, we show that administration of anti-resorptive agents such as the bisphosphonate alendronate accelerates osteonecrosis promoted by infectious osteomyelitis. Potent suppression of bone turnover by these types of agents is considered critical for osteonecrosis development; however, using mouse models we found that acceleration of bone turnover by teriparatide injection did not prevent osteonecrosis but rather converted osteoclast progenitors to macrophages expressing inflammatory cytokines, which were required for osteonecrosis development. In fact, we demonstrate that TNFα-, IL-1α/β- or IL-6-deficient mice as well as wild-type mice administered a TNFα-inhibitor were significantly resistant to development of osteonecrosis accompanying infectious myelitis, even under bisphosphonate treatment. Our data provide new insight into mechanisms underlying osteonecrosis and suggest new ways to prevent it.

Original languageEnglish
Article number46322
JournalScientific Reports
Volume7
DOIs
Publication statusPublished - 2017 Apr 7

Fingerprint

Osteonecrosis
Osteomyelitis
Cytokines
Pharmaceutical Preparations
Bone Remodeling
Diphosphonates
Therapeutics
Teriparatide
Myelitis
Alendronate
Proxy
Osteoclasts
Jaw
Interleukin-1
Bacterial Infections
Tooth
Macrophages
Bone and Bones
Injections

ASJC Scopus subject areas

  • General

Cite this

Elevation of pro-inflammatory cytokine levels following anti-resorptive drug treatment is required for osteonecrosis development in infectious osteomyelitis. / Morita, Mayu; Iwasaki, Ryotaro; Sato, Yuiko; Kobayashi, Tami; Watanabe, Ryuichi; Oike, Takatsugu; Nakamura, Satoshi; Keneko, Yosuke; Miyamoto, Kana; Ishihara, Kazuyuki; Iwakura, Yoichiro; Ishii, Ken; Matsumoto, Morio; Nakamura, Masaya; Kawana, Hiromasa; Nakagawa, Taneaki; Miyamoto, Takeshi.

In: Scientific Reports, Vol. 7, 46322, 07.04.2017.

Research output: Contribution to journalArticle

Morita, M, Iwasaki, R, Sato, Y, Kobayashi, T, Watanabe, R, Oike, T, Nakamura, S, Keneko, Y, Miyamoto, K, Ishihara, K, Iwakura, Y, Ishii, K, Matsumoto, M, Nakamura, M, Kawana, H, Nakagawa, T & Miyamoto, T 2017, 'Elevation of pro-inflammatory cytokine levels following anti-resorptive drug treatment is required for osteonecrosis development in infectious osteomyelitis', Scientific Reports, vol. 7, 46322. https://doi.org/10.1038/srep46322
Morita, Mayu ; Iwasaki, Ryotaro ; Sato, Yuiko ; Kobayashi, Tami ; Watanabe, Ryuichi ; Oike, Takatsugu ; Nakamura, Satoshi ; Keneko, Yosuke ; Miyamoto, Kana ; Ishihara, Kazuyuki ; Iwakura, Yoichiro ; Ishii, Ken ; Matsumoto, Morio ; Nakamura, Masaya ; Kawana, Hiromasa ; Nakagawa, Taneaki ; Miyamoto, Takeshi. / Elevation of pro-inflammatory cytokine levels following anti-resorptive drug treatment is required for osteonecrosis development in infectious osteomyelitis. In: Scientific Reports. 2017 ; Vol. 7.
@article{b6925b8bb4ed4df0bdabc038cd04fac9,
title = "Elevation of pro-inflammatory cytokine levels following anti-resorptive drug treatment is required for osteonecrosis development in infectious osteomyelitis",
abstract = "Various conditions, including bacterial infection, can promote osteonecrosis. For example, following invasive dental therapy with anti-bone resorptive agents, some patients develop osteonecrosis in the jaw; however, pathological mechanisms underlying these outcomes remain unknown. Here, we show that administration of anti-resorptive agents such as the bisphosphonate alendronate accelerates osteonecrosis promoted by infectious osteomyelitis. Potent suppression of bone turnover by these types of agents is considered critical for osteonecrosis development; however, using mouse models we found that acceleration of bone turnover by teriparatide injection did not prevent osteonecrosis but rather converted osteoclast progenitors to macrophages expressing inflammatory cytokines, which were required for osteonecrosis development. In fact, we demonstrate that TNFα-, IL-1α/β- or IL-6-deficient mice as well as wild-type mice administered a TNFα-inhibitor were significantly resistant to development of osteonecrosis accompanying infectious myelitis, even under bisphosphonate treatment. Our data provide new insight into mechanisms underlying osteonecrosis and suggest new ways to prevent it.",
author = "Mayu Morita and Ryotaro Iwasaki and Yuiko Sato and Tami Kobayashi and Ryuichi Watanabe and Takatsugu Oike and Satoshi Nakamura and Yosuke Keneko and Kana Miyamoto and Kazuyuki Ishihara and Yoichiro Iwakura and Ken Ishii and Morio Matsumoto and Masaya Nakamura and Hiromasa Kawana and Taneaki Nakagawa and Takeshi Miyamoto",
year = "2017",
month = "4",
day = "7",
doi = "10.1038/srep46322",
language = "English",
volume = "7",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Elevation of pro-inflammatory cytokine levels following anti-resorptive drug treatment is required for osteonecrosis development in infectious osteomyelitis

AU - Morita, Mayu

AU - Iwasaki, Ryotaro

AU - Sato, Yuiko

AU - Kobayashi, Tami

AU - Watanabe, Ryuichi

AU - Oike, Takatsugu

AU - Nakamura, Satoshi

AU - Keneko, Yosuke

AU - Miyamoto, Kana

AU - Ishihara, Kazuyuki

AU - Iwakura, Yoichiro

AU - Ishii, Ken

AU - Matsumoto, Morio

AU - Nakamura, Masaya

AU - Kawana, Hiromasa

AU - Nakagawa, Taneaki

AU - Miyamoto, Takeshi

PY - 2017/4/7

Y1 - 2017/4/7

N2 - Various conditions, including bacterial infection, can promote osteonecrosis. For example, following invasive dental therapy with anti-bone resorptive agents, some patients develop osteonecrosis in the jaw; however, pathological mechanisms underlying these outcomes remain unknown. Here, we show that administration of anti-resorptive agents such as the bisphosphonate alendronate accelerates osteonecrosis promoted by infectious osteomyelitis. Potent suppression of bone turnover by these types of agents is considered critical for osteonecrosis development; however, using mouse models we found that acceleration of bone turnover by teriparatide injection did not prevent osteonecrosis but rather converted osteoclast progenitors to macrophages expressing inflammatory cytokines, which were required for osteonecrosis development. In fact, we demonstrate that TNFα-, IL-1α/β- or IL-6-deficient mice as well as wild-type mice administered a TNFα-inhibitor were significantly resistant to development of osteonecrosis accompanying infectious myelitis, even under bisphosphonate treatment. Our data provide new insight into mechanisms underlying osteonecrosis and suggest new ways to prevent it.

AB - Various conditions, including bacterial infection, can promote osteonecrosis. For example, following invasive dental therapy with anti-bone resorptive agents, some patients develop osteonecrosis in the jaw; however, pathological mechanisms underlying these outcomes remain unknown. Here, we show that administration of anti-resorptive agents such as the bisphosphonate alendronate accelerates osteonecrosis promoted by infectious osteomyelitis. Potent suppression of bone turnover by these types of agents is considered critical for osteonecrosis development; however, using mouse models we found that acceleration of bone turnover by teriparatide injection did not prevent osteonecrosis but rather converted osteoclast progenitors to macrophages expressing inflammatory cytokines, which were required for osteonecrosis development. In fact, we demonstrate that TNFα-, IL-1α/β- or IL-6-deficient mice as well as wild-type mice administered a TNFα-inhibitor were significantly resistant to development of osteonecrosis accompanying infectious myelitis, even under bisphosphonate treatment. Our data provide new insight into mechanisms underlying osteonecrosis and suggest new ways to prevent it.

UR - http://www.scopus.com/inward/record.url?scp=85017281578&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017281578&partnerID=8YFLogxK

U2 - 10.1038/srep46322

DO - 10.1038/srep46322

M3 - Article

C2 - 28387378

AN - SCOPUS:85017281578

VL - 7

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 46322

ER -